Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2025

Conditions

Advanced Malignant Solid NeoplasmCholangiocarcinomaMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm

Interventions

DRUG

Infigratinib

Given PO

Trial Locations (1)

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

Sameek Roychowdhury

OTHER